Kidney Disease Clinical Trial
Official title:
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
This study will evaluate whether earlier intervention with vitamin D in stage II/III chronic kidney disease will prevent or delay secondary hyperparathyroidism. Subjects will receive vitamin D or placebo at study entry and will be followed for a period of one year. The hypothesis is that subjects given vitamin D will have lower PTH and higher 25(OH)D after 1 year compared to placebo. Additionally, there will be less subjects who progress into secondary hyperparathyroidism in the vitamin D treated group compared to the placebo treated group.
Vitamin D is important to maintain normal calcium homeostasis and optimal bone health (1,
2). The synthesis of vitamin D and its metabolism to 1,25(OH)2D is regulated by parathyroid
hormone (PTH), serum calcium, and phosphorus levels. In response to low serum calcium level,
serum PTH activates alpha-1-hydroxylase for increased 1,25(OH)2D production in the kidney
and also enhances tubular reabsorption of calcium (3). The higher levels of 1, 25(OH)2D
results in increased intestinal calcium absorption (4). Increased serum phosphorus levels
which occurs in the early stages of chronic kidney disease (CKD) results in inhibition of
the 1-alpha-hydroxylase, which results in decreased 1, 25(OH)2 D production, decreased
intestinal calcium absorption leading to secondary hyperparathyroidism with increased PTH
levels. Circulating 1,25(OH)2D levels begin to fall when the glomerular filtration rate is
less than 40 mL/min occasionally even less than 80 mL/min (11) and almost always
significantly reduced in subjects with end-stage renal failure (12). Furthermore, in CKD,
decreased renal mass also results in decreased expression of 1-alpha-hydroxlase and less
production of 1,25(OH)2D which also exacerbates secondary hyperparathyroidism (5-7).
Therefore, in CKD there are three processes that lead to secondary hyperparathyroidism. 1)
decreased renal mass leading to decreased production of 1,25(OH)2D leading to a compensatory
rise in PTH to further enhance production of 1,25(OH)2D 2) inhibition of the renal
1-alpha-hydroxylase by accumulating phosphorus levels leading to decreased 1,25(OH)2D which
also leads to secondary hyperparathyroidism. 3) increased phosphorus leads to lower ionized
calcium leading to increased parathyroid hormone secretion.
Untreated secondary hyperparathyroidism can lead to renal osteodystrophy (9) and increased
mortality due to cardiovascular disease (10). Prolonged secondary hyperparathyroidism can
lead to bone resorption and eventually autonomous parathyroid hormone secretion termed
tertiary hyperparathyroidism.
Vitamin D status is one of the major factors that may prevent progression of secondary
hyperparathyroidism in patients with CKD. Insufficient levels of 25-hydroxyvitamin D further
exacerbate secondary hyperparathyroidism by not providing adequate substrate for the renal
1-alpha-hydroxylase for conversion to the active form of vitamin D, 1,25(OH)2D. A recent
cross-sectional study on patients with moderate to severe CKD not yet on dialysis therapy
from 12 geographically diverse regions of the United States has shown that only 29% and 17%
of them had sufficient level, respectively (13). Vitamin D status is easily corrected. In
our previous study we concluded that weekly cholecalciferol supplementation was an effective
treatment to correct vitamin D status in patients with CKD stages III and IV (14). However,
PTH levels did not return to normal. Therefore, it is likely that earlier intervention with
vitamin D is necessary to prevent rather than to treat secondary hyperparathyroidism. This
is the major question that is being evaluated in this study. Can intervening with vitamin D
at an earlier stage of chronic kidney disease result in decreased incidence of secondary
hyperparathyroidism?
2.0 Objectives
2.1 Overall Objective
The primary objective of this study is to assess that if improving and maintaining an
optimal 25(OH) D level ( by National Kidney Foundation should be greater than 30ng/ml) (15)
in people with stage II/III Chronic Kidney disease would delay the progression of secondary
hyperparathyroidism and translate into improved markers of bone turnover
2.2 Specific Aims
Primary: 1) To determine in a double blind, randomized study whether supplementation with
50,000 IU of cholecalciferol (vitamin D3) given weekly for 12 weeks followed by maintenance
cholecalciferol 50,000 IU every other week would improve and maintain vitamin D status in
CKD patients stage 2/3 compared to placebo at 12 months.
2) To determine whether early intervention with vitamin D therapy further decreases PTH
levels after 12 weeks of therapy and 12 months of therapy.
Secondary: 1) To determine whether early treatment with vitamin D results in improving
levels of bone turnover markers- tartrate-resistant acid phosphatase isoform 5b(TRAP5b),
procollagen Type 1 N-Terminal propeptide (PINP), serum C-Telopeptide and Alkaline
phosphatase.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02369354 -
Transplant Social Worker Support for Live Kidney Donation in African Americans
|
N/A | |
Not yet recruiting |
NCT02225782 -
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
|
Phase 4 | |
Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
Terminated |
NCT00436748 -
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
Completed |
NCT01235936 -
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
|
Phase 2 | |
Completed |
NCT01947829 -
Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)
|
N/A | |
Completed |
NCT01974999 -
A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
|
||
Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
Active, not recruiting |
NCT01228903 -
Uric Acid and the Endothelium is CKD
|
N/A | |
Completed |
NCT00734357 -
Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients
|
N/A | |
Completed |
NCT00093977 -
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT00185159 -
Olmesartan Medoxomil in Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT00096915 -
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
|
Phase 3 | |
Completed |
NCT00094484 -
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
|
Phase 3 |